Safety and Efficacy of Corneal Cross-Linking in Patients Affected by Keratoconus: Long-Term Results.
Karl Anders KnutssonPaola Noemi GenoveseGiorgio PaganoniOriella AmbrosioGiulio FerrariArianna ZennatoMichela CacciaMadeleine CataldoPaolo RamaPublished in: Medical sciences (Basel, Switzerland) (2023)
The present study evaluated the effectiveness and safety of corneal collagen cross-linking (CXL). A total of 886 eyes with progressive keratoconus were enrolled in a retrospective cohort study in a tertiary care university hospital. CXL was performed using a standard epithelium-off Dresden protocol. Visual outcomes, maximum keratometry (Kmax), demarcation line measurements, and complications were recorded. Visual outcomes and keratometric data were analyzed in a subgroup comprising 610 eyes. Uncorrected distance visual acuity (UDVA) improved from 0.49 ± 0.38 LogMAR to 0.47 ± 0.39 LogMAR ( p = 0.03, n = 610) three years after the procedure, while corrected distance visual acuity (CDVA) improved from 0.15 ± 0.14 LogMAR to 0.14 ± 0.15 LogMAR ( p = 0.007, n = 610). A significant reduction of Kmax from 56.28 ± 6.10 to 54.98 ± 6.19 ( p < 0.001, n = 610) was observed three years after CXL. In five eyes (0.82%, 5/610) keratoconus progression continued after CXL. Three eyes were retreated successfully with documented refractive and topographic stability after five years. In the 35 eyes that completed 10 years of follow-up, mean visual acuity and topographic parameters remained stable. In conclusion, CXL is a safe and effective treatment for avoiding keratoconus progression. Long-term data are encouraging, supporting a high safety profile for this procedure.
Keyphrases
- optical coherence tomography
- cataract surgery
- tertiary care
- end stage renal disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- electronic health record
- multiple sclerosis
- minimally invasive
- chronic kidney disease
- big data
- wound healing
- prognostic factors
- risk factors
- metabolic syndrome
- adipose tissue
- artificial intelligence
- clinical trial
- skeletal muscle
- data analysis
- phase iii
- insulin resistance
- tissue engineering